Views & Analysis Is the launch environment really more competitive now? It’s often stated - mostly without reference to data - that the environment for innovative launches is more competitive now than it ever has been. Is this true?
News MSD adds new indication for Welireg in rare tumours MSD's oral HIF-2 alpha inhibitor Welireg has a third FDA approval, becoming the first oral treatment for a rare solid tumour PPGL or 'pheo para'.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.